Phaseline

Companies › Upsher-Smith Laboratories

Upsher-Smith Laboratories: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 4 Phase 4, 1 Phase 2; Neurology, Metabolic and endocrine, Psychiatry.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Topiramate
Carbonic anhydrase II inhibitor; Carbonic anhydrase IV inhibitor; Glutamate receptor ionotropic AMPA antagonist
CA2, CA4, GRIA4, GRIA3, GRIA2Phase 4Migraine Disorders; Obesity; Ménière; Liver Cirrhoses …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03667846TopiramatePhase 2Post Traumatic Stress DisorderPsychiatryAug 2025
NCT04748601TopiramatePhase 4Migraine DisordersNeurologySep 2026
NCT05975580TopiramatePhase 4ObesityMetabolic and endocrineJul 2027
NCT05582837TopiramatePhase 4MénièreNeurologyDec 2027
NCT07058155TopiramatePhase 4Liver CirrhosesMetabolic and endocrineFeb 2029

Targets

CA2 (1) CA4 (1) GRIA4 (1) GRIA3 (1) GRIA2 (1)

Companies with the same targets

Neurocrine Biosciences Eisai Proniras Shionogi Tecnoquimicas Incannex Healthcare

Companies built like this

Impax Laboratories IntraBio Zhejiang Hanmai Pharmaceutical Technology Sichuan Jishengtang Pharmaceutical Idorsia Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.